REGLAN (metoclopramide hydrochloride) by ANI Pharmaceuticals is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. First approved in 1980.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
REGLAN (metoclopramide HCl) is an oral small-molecule dopamine antagonist approved in 1980 for gastrointestinal motility disorders and nausea/vomiting. It works by sensitizing GI tissues to acetylcholine and blocking dopamine receptors in the chemoreceptor trigger zone, accelerating gastric emptying and increasing lower esophageal sphincter pressure. It is primarily used in gastroesophageal reflux disease, diabetic gastroparesis, and post-operative nausea.
With loss of exclusivity approaching and modest Part D spending ($88K, 155 claims in 2023), the brand team is likely small and focused on generic competition mitigation rather than growth initiatives.
CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…
Worked on REGLAN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on REGLAN offers limited career growth potential given its LOE-approaching status, minimal branded spending, and zero linked job postings. Roles tend to focus on regulatory maintenance, generic competition response, and operational efficiency rather than innovation, making this a transition or stabilization role rather than a launching pad for advancement.